The medical representative filing system is coming! The pharmaceutical industry may change

"Pharmaceutical Network Industry Dynamics" Recently, the Chinese Pharmaceutical Society issued a "notice on the development of pharmaceutical representatives to record the use of the platform" in the pharmaceutical industry.
the notice, the State Drug Administration intends to formally issue the Measures for the Administration of the Filing of Pharmaceutical Representatives (Trial) in the near future, and the Chinese Pharmaceutical Society has been entrusted by the State Drug Administration to undertake the construction and maintenance of the filing platform for pharmaceutical representatives.
, the industry believes that the pharmaceutical representative filing system, really is coming! In fact, as early as June 5 this year, the State Drug Administration issued the "Pharmaceutical Representative Filing Management Measures (Trial) (Draft for Comments)" public consultation, pointed out that the Chinese Pharmaceutical Society is the National "Pharmaceutical Representative Filing Management Measures" filing platform of the contractor and maintenance institutions.
Of course, in addition to this document, it is even more noteworthy that the implementation date signed under the draft pending high-level approval is still to be implemented on a certain day in 2020, and it is clear that the landing of the filing system for pharmaceutical representatives is something that must be completed this year."
it is understood that the Measures for the Administration of the Filing of Medical Representatives (Trial) (Draft for Review) and the previous Draft for Comments are not different in the main matters.
And according to the previously issued Draft for Comments, it is worth noting that the pharmaceutical representative has been defined, clearly referred to as the pharmaceutical representative refers to on behalf of the drug market license holders in China engaged in drug information transmission, communication, feedback professionals, its main responsibilities include: academic promotion, technical advice, to assist medical personnel to use drugs rationally, collect, feedback on the clinical use of drugs and adverse drug reaction information.
addition, the Draft also lists five forms of academic promotion by medical representatives, including face-to-face communication with medical personnel in medical institutions, organization of society meetings, lectures, and the provision of academic materials.
and clearly state that pharmaceutical representatives shall not undertake the task of drug sales, collect money and process purchase and sale bills, and shall not participate in the counting of the number of drug prescriptions issued by individual doctors.
fact, the return of medical representatives to the academic standard is a common feature of the control of relevant national documents in recent years.
Industry insiders said that since the 1980s, foreign companies set up pharmaceutical representatives gradually in the domestic promotion, pharmaceutical representatives also gradually expanded from the academic promotion standard to product sales, calling on pharmaceutical representatives to return to the academic standard has gradually become the focus of national control and consensus.
as early as 2015, the profession of pharmaceutical representative was first included in the General Classification of Occupations, and its academic promotion of the content of the work.
2017, the State issued the Opinions on Deepening the Reform of the Review and Approval System to Encourage Drug Medical Device Innovation, which clearly stated that the academic promotion of pharmaceutical drugs should be regulated, and that pharmaceutical representatives should be responsible for the academic promotion of pharmaceuticals.
pharmaceutical representative is not a salespable person and should not undertake the task of drug sales.
The newly amended Drug Administration Law of 2019 also explicitly prohibits drug market license holders, pharmaceutical manufacturers, pharmaceutical manufacturers and medical institutions from giving, receiving kickbacks or other improper benefits in the purchase and sale of drugs.
, while encouraging innovation in recent years, the state has also further standardized the development of the industry.
the future, there will be more opportunities for drug companies to invest in drug innovation and compliance promotion.
Because whether it is the initial two-vote system, or the current volume of procurement, have played a role in non-compliant marketing promotion, when the circulation channels, drug prices tend to rational, the management and norms of pharmaceutical representatives have also been raised from the national level on the agenda.
this background, professional medical representatives will be more useful in the future.